Literature DB >> 21706448

Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP.

Dana Provaznikova1, Simon Rittich, Michal Malina, Tomas Seeman, Iuri Marinov, Magdalena Riedl, Ingrid Hrachovinova.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Mutations in genes encoding regulators of the alternative complement pathway (CFH, MCP, C3, CFI, CFB, THBD, and CFHR1-5) are connected with this disease. Polymorphisms (SNPs) in these genes might also influence the manifestation of aHUS. We have analyzed the genes of CFH, CFI, MCP, and C3 in a cohort of 10 unrelated Czech patients with clinically diagnosed familial aHUS. Surprisingly, 4 patients had mutations only in MCP, without mutations in any of the other genes that cause aHUS. Mutations, as yet unpublished, were widely distributed over the gene (SCR2 domain, signal peptide, and cytoplasmic region). The phenotype of the patients and their close relatives (14 individuals) was also investigated. Functional examination of MCP was also provided and proved lower expression on granulocytes in all mutations. Severity of disease varied, but onset was never earlier than 5 years of age. Penetrance of disease was 50% among carriers. We found that the severity and recurrence of the disease within families varied and might also be dependent on SNPs. Mutations in the MCP gene seems to be a common etiology of aHUS in Czech patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706448     DOI: 10.1007/s00467-011-1943-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  27 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Genetic studies into inherited and sporadic hemolytic uremic syndrome.

Authors:  P Warwicker; T H Goodship; R L Donne; Y Pirson; A Nicholls; R M Ward; P Turnpenny; J A Goodship
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

3.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 4.  Escherichia coli O157:H7 and the hemolytic-uremic syndrome.

Authors:  T G Boyce; D L Swerdlow; P M Griffin
Journal:  N Engl J Med       Date:  1995-08-10       Impact factor: 91.245

5.  Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46).

Authors:  M K Liszewski; M Leung; W Cui; V B Subramanian; J Parkinson; P N Barlow; M Manchester; J P Atkinson
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

6.  Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome.

Authors:  Tara K Maga; Carla J Nishimura; Amy E Weaver; Kathy L Frees; Richard J H Smith
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

7.  Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome.

Authors:  Maren Sullivan; Zoran Erlic; Michael M Hoffmann; Klaus Arbeiter; Ludwig Patzer; Klemens Budde; Bernd Hoppe; Martin Zeier; Karl Lhotta; Lisa A Rybicki; Andreas Bock; Gani Berisha; Hartmut P H Neumann
Journal:  Ann Hum Genet       Date:  2010-01       Impact factor: 1.670

8.  Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.

Authors:  Mihály Józsi; Christoph Licht; Stefanie Strobel; Svante L H Zipfel; Heiko Richter; Stefan Heinen; Peter F Zipfel; Christine Skerka
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

9.  Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.

Authors:  Celia J Fang; Veronique Fremeaux-Bacchi; M Kathryn Liszewski; Gaia Pianetti; Marina Noris; Timothy H J Goodship; John P Atkinson
Journal:  Blood       Date:  2007-10-03       Impact factor: 22.113

10.  Hemolytic uremic syndrome recurrence after renal transplantation.

Authors:  Chantal Loirat; Véronique Fremeaux-Bacchi
Journal:  Pediatr Transplant       Date:  2008-05-10
View more
  8 in total

Review 1.  Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.

Authors:  Maurizio Salvadori; Giuseppina Rosso; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2015-05-06

2.  First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.

Authors:  Selçuk Yüksel; Havva Evrengül; Z Birsin Özçakar; Tülay Becerir; Nagihan Yalçın; Emine Korkmaz; Fatih Ozaltin
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

3.  Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.

Authors:  Liang Zheng; Di Zhang; Wenjing Cao; Wen-Chao Song; X Long Zheng
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

Review 4.  Complement regulator CD46: genetic variants and disease associations.

Authors:  M Kathryn Liszewski; John P Atkinson
Journal:  Hum Genomics       Date:  2015-06-10       Impact factor: 4.639

Review 5.  Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.

Authors:  Fengxiao Bu; Nicolo Borsa; Ardissino Gianluigi; Richard J H Smith
Journal:  Clin Dev Immunol       Date:  2012-11-08

Review 6.  The complement cascade and renal disease.

Authors:  Katarzyna Kościelska-Kasprzak; Dorota Bartoszek; Marta Myszka; Marcelina Zabińska; Marian Klinger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-09-13       Impact factor: 4.291

7.  FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.

Authors:  Nóra Garam; Marcell Cserhalmi; Zoltán Prohászka; Ágnes Szilágyi; Nóra Veszeli; Edina Szabó; Barbara Uzonyi; Attila Iliás; Christof Aigner; Alice Schmidt; Martina Gaggl; Gere Sunder-Plassmann; Dóra Bajcsi; Jürgen Brunner; Alexandra Dumfarth; Daniel Cejka; Stefan Flaschberger; Hana Flögelova; Ágnes Haris; Ágnes Hartmann; Andreas Heilos; Thomas Mueller; Krisztina Rusai; Klaus Arbeiter; Johannes Hofer; Dániel Jakab; Mária Sinkó; Erika Szigeti; Csaba Bereczki; Viktor Janko; Kata Kelen; György S Reusz; Attila J Szabó; Nóra Klenk; Krisztina Kóbor; Nika Kojc; Maarten Knechtelsdorfer; Mario Laganovic; Adrian Catalin Lungu; Anamarija Meglic; Rina Rus; Tanja Kersnik Levart; Ernesta Macioniene; Marius Miglinas; Anna Pawłowska; Tomasz Stompór; Ludmila Podracka; Michael Rudnicki; Gert Mayer; Romana Rysava; Jana Reiterova; Marijan Saraga; Tomáš Seeman; Jakub Zieg; Eva Sládková; Natasa Stajic; Tamás Szabó; Andrei Capitanescu; Simona Stancu; Miroslav Tisljar; Kresimir Galesic; András Tislér; Inga Vainumäe; Martin Windpessl; Tomas Zaoral; Galia Zlatanova; Mihály Józsi; Dorottya Csuka
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

8.  Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

Authors:  Teresa Fidalgo; Patrícia Martinho; Catarina S Pinto; Ana C Oliveira; Ramon Salvado; Nina Borràs; Margarida Coucelo; Licínio Manco; Tabita Maia; M João Mendes; Rafael Del Orbe Barreto; Irene Corrales; Francisco Vidal; M Letícia Ribeiro
Journal:  Res Pract Thromb Haemost       Date:  2017-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.